BioStock: Cereno Scientific intends to initiate a phase II study in September
At the end of last week, Cereno Scientific announced that the timeline for the upcoming phase II trial with drug candidate CS1 has been set. The announcement comes after the signing of the final collaboration agreement with clinical research organisation (CRO) Worldwide Clinical Trials. According to the timeline, the first patient with the rare disease pulmonary arterial hypertension (PAH) will receive treatment in September 2021, and study results will be presented during the second half of 2022.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se